RT Journal Article
SR Electronic
T1 Taking Control of Your Functional Cognitive Symptoms Workbook: A Novel Intervention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.15.24315532
DO 10.1101/2024.10.15.24315532
A1 Cotton, E.
A1 Mordecai, K. L.
A1 McWhirter, L.
A1 Cabreira, V.
A1 Van Patten, R.
A1 Silverberg, N.D.
A1 Kaat, A.J.
A1 LaFrance, W.C.
YR 2024
UL http://medrxiv.org/content/early/2024/10/19/2024.10.15.24315532.abstract
AB Background Functional cognitive disorder (FCD) is a subtype of functional neurological disorder (FND). FCD can present with various cognitive symptoms, precipitants, and comorbidities (other FNDs, concussion, fatigue, fibromyalgia, etc.). However, there are no widely available existing behavioral health interventions for FCD. The authors’ aim was to develop a therapist-guided treatment for FCD for widespread use among civilians and Veterans.Methods We adapted a well-known, evidence-based treatment for functional seizures (an adjacent condition often with cognitive symptoms), to fit the hypothesized mechanisms of FCD. The process is presented in GUIDED format (GUIDance for the rEporting of intervention Development). Key processes included determining broad intervention framework, detailed FCD specific content based on expert consensus, evidence, theory, target population centered approaches, specialty subgroup consideration and target population stakeholder feedback for Veteran and civilian populations.Findings We have created a comprehensive 14-chapter, manualized, therapist-guided neurobehavioral therapy protocol to target FCD symptoms independent of etiology – the Taking Control of Your Functional Cognitive Symptoms Workbook. Initial feasibility, tolerability, and utility were completed with 2 target population stakeholders with FCD (one civilian, one Veteran; both PGI-C rating = 1 “Very Much Improved”). The Template for Intervention Description and Replication (TIDieR) checklist is provided as a supplemental table.Interpretation This new promising multi-modality behavioral health intervention can be considered Stage 1 (i.e. intervention generation, refinement, modification, adaptation, and pilot testing). Further pilot testing is being conducted and will need to be followed by traditional efficacy testing (Stage 2).Key MessagesFCD is an increasingly recognized subtype of FND. Despite existing models of FCD mechanisms, there are no widely available dedicated FCD-symptom focused behavioral health interventions.We have created the Taking Control of Your Functional Cognitive Symptoms: Workbook, a 14-chapter manualized therapist-guided neurobehavioral therapy protocol to target FCD symptoms regardless of cause / associated conditions, which shows early feasibility and promising clinical utility.Competing Interest StatementEC: E. Cotton receives funding from the Northwesterns Womens Board and holds a non-paid role on the Medical Advisory Counsel of the Epilepsy Foundation of Chicago. RVP: R. Van Patten receives funding from VA Providence, RR&D Center for Neurorestoration and Neurotechnology. He engages in profit sharing with the International Neuropsychological Society for Continuing Education proceeds from the Navigating Neuropsychology podcast. He also receives royalties from publication of the book, Becoming a Neuropsychologist: Advice and Guidance for Students and Trainees (Springer, 2021). The research reported/outlined here was supported by the Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award to R. Van Patten. WCL: Curt LaFrance Jr. has served on the editorial boards of Epilepsia, Epilepsy & Behavior; Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Neuropsychiatry and Clinical Neurosciences; receives editors royalties from the publication of Gates and Rowans Nonepileptic Seizures, 3rd ed. (Cambridge University Press, 2010) and 4th ed. (2018); authors royalties for Taking Control of Your Seizures: Workbook and Therapist Guide (Oxford University Press, 2015); has received research support from the Department of Defense (DoD W81XWH-17-0169), NIH (NINDS 5K23NS45902 [PI], VA Providence HCS, Center for Neurorestoration and Neurorehabilitation, Rhode Island Hospital, the American Epilepsy Society (AES), the Epilepsy Foundation (EF), Brown University and the Siravo Foundation; has served on the Epilepsy Foundation New England Professional Advisory Board, the Functional Neurological Disorder Society Board of Directors, the American Neuropsychiatric Association Advisory Council; has received honoraria for the AES and AAN Annual Meetings; has served as a clinic development consultant at University of Colorado Denver, Cleveland Clinic, Spectrum Health, Emory University, Oregon Health Sciences University and Vanderbilt University; and has provided medico legal expert testimony. NDS: N. Silverberg has received research operating funds from multiple granting agencies (Canada Foundation for Innovation, Canadian Institutes of Health Research, Mitacs, Ontario Brain Institute, US Department of Defense, WorkSafeBC, VGH+UBC Hospital Foundation) for research related to traumatic brain injury diagnosis, prognosis, and treatment. He has received speaker fees for providing continuing medical education on these topics. He serves as chair of the American Congress of Rehabilitation Medicines Brain Injury Special Interest Group Task Force on Mild TBI (unpaid). He has served as an expert panel member for the Living Concussion Guidelines and as an external reviewer for other clinical practice guidelines on concussion/TBI (unpaid). He has provided expert testimony and medical-legal consulting in the past 5 years (<10% of total income). VC: V. Cabreira has received funding from the European Unions Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 956673. This article reflects only the authors views, the Agency is not responsible for any use that may be made of the information it contains. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Northwestern University gave ethical approval for this work. Further, participants provided consent (including consent to publish).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors